Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000187058 | SCV000240632 | uncertain significance | not provided | 2015-04-27 | criteria provided, single submitter | clinical testing | The c.2 T>C nucleotide substitution has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. This substitution alters the initiator Methionine codon, and the resultant protein would be described as p.Met1?" to signify that it is not known if the loss of Met1 means that all protein translation is completely prevented or if a protein is produced using an alternative Methionine initiator codon. The c.2 T>C variant was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, but the 1000 Genomes Project reports c.2 C>T was observed as an apparently homozygous variant in one individual of Finnish ancestry. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant." |
Counsyl | RCV000672217 | SCV000797304 | uncertain significance | Neuronal ceroid lipofuscinosis 5 | 2018-01-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000672217 | SCV002027045 | uncertain significance | Neuronal ceroid lipofuscinosis 5 | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002054194 | SCV002415047 | likely benign | Neuronal ceroid lipofuscinosis | 2022-01-03 | criteria provided, single submitter | clinical testing |